Compare CAR-T cell therapy access, leading hematology cancer centers, apheresis timelines, and inpatient monitoring in China.
China is a global powerhouse in CAR-T cell therapy research, hosting more active clinical trials and commercially approved cellular targets than almost any other country, with significant cost advantages.
Why compare
What changes choice
Good fit
Breakthrough response rates in relapsed/refractory multiple myeloma (BCMA) and non-Hodgkin lymphoma (CD19).
Significantly lower overall total treatment expenditure compared to US/European commercial cell therapies ($300k+ vs $60k-$100k in China).
High-volume clinical experience managing cytokine release syndrome (CRS) and ICANS neurotoxicity in specialized hematologic ICUs.
Availability of innovative dual-target CAR-T constructs and investigator-initiated trials (IIT) for difficult cases.
Confirm whether BCMA, CD19, CD22, or dual-targeted constructs match prior treatment history and immunophenotype.
Select recognized national hematology medical centers with dedicated apheresis and cleanroom cell processing infrastructure.
Evaluate bridging chemotherapy requirements between leukapheresis and cell infusion (typically 2-4 weeks).
Plan for a mandatory 3 to 4-week inpatient monitoring period post-infusion for CRS surveillance.
Institutes such as Ruijin Hospital (Shanghai), Cancer Hospital CAMS (Beijing), and West China Hospital with dedicated cell therapy wings.
Premier academic centers running state-of-the-art IIT protocols and commercial CAR-T infusion protocols with dedicated foreign patient coordinators.
Pre-evaluation & Triage: 3-5 days for blood testing, marrow biopsy review, and apheresis eligibility.
T-cell Collection (Apheresis): 1-2 days.
Cell Manufacturing & Bridging: 14-28 days depending on construct type.
Lymphodepleting Conditioning: 3 days of Cy/Flu chemotherapy.
Infusion & CRS Observation: 21-28 days of close inpatient supervision.
Compare oncology departments, radiotherapy, second opinions, PET-CT, and treatment pathway planning.
Explore categoryReview how patients compare oncology departments, imaging access, and record-based second-opinion pathways in China.
View detailsSee how patients compare MRI access, scan costs, and hospital options before arranging diagnostic imaging in China.
View detailsCompare CT scan access, pricing, and hospital pathways before arranging diagnostic imaging in China.
View detailsShort answers before you decide whether this path is worth comparing.
Most patients need approximately 6 to 8 weeks: 1 week for intake and apheresis, 2-3 weeks of bridging/manufacturing, and 3-4 weeks of post-infusion inpatient observation.
Recent bone marrow aspiration & biopsy with cytogenetics/FISH, PET-CT DICOM scans, flow cytometry reports, and a detailed summary of all prior systemic therapy lines.
Top Chinese centers stock immediate supplies of Tocilizumab (IL-6 receptor antagonist) and steroids with dedicated hematologic ICU beds on standby 24/7.
Compare likely costs, hospital options, and planning steps before you contact providers or arrange travel.
